Note: This is an experiment with a different style of blog post, aiming to more casually share thoughts from a broader set of staff. We’re interested in feedback on this format.
Earlier this year, the Open Philanthropy Project awarded a five-year grant and made an additional investment in Sherlock Biosciences to support the development of a diagnostic platform to quickly, easily, and inexpensively identify any human virus present in a patient sample.
Development of this technology would represent a significant advance in viral diagnosis, and could both reduce threats from viral pandemics and also benefit health care broadly. In one implementation of the test, which might be suitable for use in field clinics or for home use, samples can be tested in less than an hour using just a strip of paper.
We believe that the broad potential of Sherlock’s technologies is matched by co-founders and a team of deeply experienced scientists, entrepreneurs, and clinicians who are aligned with our goal of making a universal viral diagnostic system available worldwide. The new company, recently spun out of the Broad Institute of MIT and Harvard, is developing technologies licensed from the Broad Institute and Harvard University’s Wyss Institute. [node:read-more:link]